Every material Form 8-K INVO Fertility, Inc. has filed with the SEC since August 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
INVO Fertility, Inc. (Nasdaq: IVF) filed a Nevada Certificate of Change to carry out a 1-for-4 reverse stock split, effective 12:01 a.m. Eastern Time on October 30, 2026. Every four shares of common stock were combined into one share, and the company's authorized shares were adjusted to 62,500,000. The split changes the per-share count and price basis for shareholders but does not change the ticker symbol, which remains IVF.
Reverse split of 1-for-4 effective 12:01 a.m. ET on October 30, 2026; stock began trading split-adjusted when Nasdaq opened that day.
Approximately 1,192,841 shares of common stock outstanding immediately after the split, per the press release.
Authorized common stock adjusted to 62,500,000 shares; option and warrant exercise prices and share counts adjusted proportionately.
New CUSIP 44984F872; shares continue to trade on The Nasdaq Capital Market as IVF. Fractional shares were rounded up for registered holders.
INVO Fertility furnished an investor presentation for use at the H.C. Wainwright 28th Annual Global Investment Conference, September 14 to 16, 2026, and disclosed that it has sold 2,094,395 shares to Alumni Capital LP under a July 24, 2026 purchase agreement for approximately $3,591,000. Shareholders may note the ongoing share sales, which add to the outstanding share count, under a facility with a commitment amount of up to $15 million that could be increased to $50 million by mutual agreement.
Investor presentation to be used at H.C. Wainwright 28th Annual Global Investment Conference, September 14 to 16, 2026, and posted to the Investors section of the company website on August 28, 2026
Shares sold to Alumni Capital LP since SEC effectiveness: 2,094,395 shares for approximately $3,591,000, at an approximate average of $1.71 per share
Purchase agreement dated July 24, 2026 allows the company to sell up to $15 million in shares, with an option to increase to $50 million by mutual written agreement
INVO Fertility reported second-quarter 2026 revenue of $2,175,485, up 17% from $1,863,654 a year earlier, mainly due to the February 2026 Family Beginnings acquisition. The company swung to net income of $888,740 from a net loss of $3,618,969, but that result includes an approximately $2.5 million remeasurement gain tied to the Birmingham clinic acquisition, while Adjusted EBITDA was a loss of $1,032,660 versus $587,229 a year earlier.
Q2 2026 revenue was $2,175,485 versus $1,863,654 in Q2 2025, an increase of 17%.
Net income was $888,740 versus a net loss of $3,618,969, including an approximately $2.5 million gain on remeasurement related to the Birmingham acquisition.
Adjusted EBITDA was $(1,032,660) versus $(587,229) in Q2 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every INVO Fertility, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →